Register Login

APTEVO THERAPEUTICS INC. (APVO)

(80% Positive) APTEVO THERAPEUTICS INC. (APVO) Announces Enrollment Update for progress Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 14, 2026, 12:11 p.m.

    📋 APTEVO THERAPEUTICS INC. (APVO) - Clinical Trial Update

    Filing Date: 2026-08-14

    Accepted: 2026-08-14 08:10:17

    Event Type: Clinical Trial Update

    Event Details:

    APTEVO THERAPEUTICS INC. (APVO) Announces Clinical Trial Update APTEVO THERAPEUTICS INC. (APVO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: progress, results
    • Diseases/Conditions: Aptevo, mipletamig
    • Collaboration: ADAPTIR-FLEX
      • planned for the first quarter of 2027
      • targeting expertise into additional cancer treatment approaches. For more information, visit www.aptevotherapeutics.com. Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
      • targeting expertise. The structure gives Aptevo a cost-efficient path into radiopharmaceutical therapeutics by sharing development costs, while pairing Aptevo’s tumor-targeting expertise with Niowave’s radioisotope production and supply capabilities. Importantly, the collaboration also provides access to isotope supply in a constrained market. Niowave also made an at-the-market equity investment in Aptevo at closing, creating additional alignment between the companies.•50/50 collaboration to develop up to three radiopharmaceutical oncology programs•Strategic equity investment by Niowave at closing, representing an initial 7.9% ownership position, with the potential to build up to 19.99%•Opportunity to extend Aptevo’s tumor-targeting approach into radiopharmaceutical therapeutics for difficult-to-treat cancers Q2 2026

    🔬 Clinical Development Pipeline (APTEVO THERAPEUTICS INC.):

    Product Type Development Stage Therapeutic Area Source
    Azacitidine Other Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    ALG.APV-527 Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Placebo Other Phase PHASE1 Psoriasis ClinicalTrials.gov
    APVO210 Other Phase PHASE1 Psoriasis ClinicalTrials.gov
    Rituximab Other Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent ClinicalTrials.gov
    Bendamustine Other Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent ClinicalTrials.gov
    TRU-016 Other Phase PHASE1 B-cell Small Lymphocytic Lymphoma Recurrent ClinicalTrials.gov
    ES414 Other Phase PHASE1 Prostate Cancer ClinicalTrials.gov
    TRU-016 10-20 mg/kg + bendamustine Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    TRU-016 10-20 mg/kg + ibrutinib Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    TRU-016 6-20 mg/kg + idelalisib + rituximab Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    TRU-016 20 mg/kg + Obinutuzumab Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    10 mg/kg TRU-016 + Rituximab Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    20 mg/kg TRU-016 + Rituximab Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    20 mg/kg TRU-016 and bendamustine Other Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov
    15 mg/kg TRU-016 and bendamustine Other Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov
    TRU-016 and bendamustine Other Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov
    APVO436 Other Phase PHASE1 AML ClinicalTrials.gov
    TRU-016 (anti-CD37 protein therapeutic) DRUG Phase PHASE1 Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: APTEVO THERAPEUTICS INC.
    • Ticker Symbol: APVO

Search

News categories